Articles tagged with Anticoagulants
In patients with advanced chronic kidney disease at high cardiovascular risk, low-dose rivaroxaban did not reduce the composite risk of a cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared to the placebo group.
Extended low-dose apixaban effectively reduced symptomatic superficial vein thrombosis (SuVT) risk. Patients with enduring risk factors for SuVT benefited from this anticoagulation strategy.
Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.
A single-group implementation trial successfully introduced warfarin patient self-management in the US healthcare system, providing critically needed evidence to accelerate its implementation. The study's results support safe and effective patient self-management of anticoagulation therapy.
A study of 470 patients who underwent free flap reconstruction found that holding blood thinners for too long increases complications. The researchers suggest that resuming blood thinners within 48 hours after surgery may be safe, reducing the risk of excessive bleeding and dangerous clotting.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
A US study found that extending anti-clotting treatment beyond 90 days reduces recurrent VTE rates by 81% and death rates by 26%, while increasing major bleeding risk. The overall 'net clinical benefit' persists even after three years of treatment.
A study of 2,201 patients after heart bypass surgery showed that dual antiplatelet therapy with ticagrelor and aspirin did not reduce cardiovascular risks but increased the risk of excessive bleeding. The results contradict current guidelines recommending dual therapy for these patients.
Researchers found that taking blood thinners like warfarin does not significantly increase the risk of brain bleeding after blunt head trauma, contradicting previous assumptions. In fact, patients with poorly controlled warfarin activity had the highest bleeding risk.
A new study published in The Lancet found that starting direct oral anticoagulants within four days of a stroke significantly reduces the risk of another stroke due to bleeding or artery blockage. Early treatment also did not increase the risk of bleeding into the brain.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A study by University of Bath researchers found that stopping anticoagulants for patients aged 75 and over does not significantly affect the risk of major bleeding, but increases the risk of serious events like stroke and death. This highlights the need for clinicians to carefully consider the risks of stopping anticoagulation therapy ...
A systematic review found that therapeutic-dose apixaban and dabigatran have bleeding risks comparable to low-dose aspirin, while rivaroxaban has higher rates of major bleeding. The study aims to help clinicians balance anticoagulant benefits with bleeding risks for patients with atrial fibrillation.
A recent study by Michigan Medicine found that reducing the dose of popular blood thinners like Xarelto and Eliquis can lower the risk of future bleeding events. The research team analyzed nearly 1,000 cases of patients who took these medications to prevent recurrent clots after having a blood clot.
A study published in the Journal of Raptor Research found that turkey vultures in southern California are still exposed to anticoagulant rodenticides, even with recent bans in place. The researchers recommend continued monitoring and adherence to legislation regarding rodenticide use.
A recent study published in Circulation found a correlation between lower levels of coagulation factor XI and an increased risk of heart failure. The research, conducted on two large community-based cohorts, also linked lower factor XI levels to a greater likelihood of atrial fibrillation and worse heart function.
Research highlights edoxaban's effectiveness in reducing stroke and blood clots for patients after bioprosthetic heart valve replacement. Edoxaban was found to be equally or more effective than warfarin, with a predictable pharmacokinetic profile and reduced burden on patients.
Research published in European Heart Journal reveals that taking an NSAID with anticoagulant medication increases the risk of internal bleeding. The study found a significant increase in bleeding risks for various organs, including gut, brain, lungs, and bladder.
Researchers found that adopting an electronic patient management system for direct oral anticoagulants reduced off-label dosing by 8%, while also decreasing the rate of blood clots and strokes. The online dashboard, used at over 120 hospitals, highlights treatment optimization and improves patient safety.
A randomized trial found that continuing oral anticoagulants after transcatheter aortic valve implantation did not reduce thromboembolic events but increased bleeding risk. The study suggests interrupting OACs may be beneficial for patients undergoing TAVI.
A study by Michigan Medicine found that over- or under-dosing anticoagulants can result in serious health conditions, most often occurring after the initial prescription. The researchers evaluated five years of prescribing data and found that nearly 70% of alerts to off-label dosing occurred during a follow-up visit.
Patients with atrial fibrillation who took low doses of direct oral anticoagulants experienced more bleeding episodes during the first three months of treatment. High blood levels of the medications were also associated with an increased risk of bleeding events.
Researchers assessed brain imaging for minor, moderate, and major ischemic strokes to evaluate early direct oral anticoagulant initiation. The study found no difference in treatment effects or adverse event rates among infarct sizes.
Black and Hispanic patients with atrial fibrillation were less likely to initiate direct oral anticoagulants at study onset, but these disparities narrowed over time. The study highlights the need to address unequal access to novel therapies for Black and Hispanic populations.
A new anticoagulant with on-demand reversible activity has been developed by a team from UNIGE and the University of Sydney. This breakthrough offers a more reliable and easier-to-use option for surgical procedures, reducing the risk of serious bleeding associated with current treatments.
Researchers have developed a new anticoagulant with an on-off switch, providing rapid control of bleeding risks in surgery and blood clots. The supramolecular approach combines a tsetse fly protein with a synthetic peptide, allowing for the anticoagulant to be rapidly deactivated by introducing correctly matched strands of free PNA.
Researchers at Rensselaer Polytechnic Institute have developed a patented process to produce heparin in the lab, offering a consistent and safe supply of the essential medicine. The discovery has the potential to revolutionize the production of heparin, reducing reliance on animal-derived sources and addressing global supply chain issues.
New research suggests that direct oral anticoagulants (DOACs) are less effective and safer in certain patient scenarios, such as those with mechanical heart valves or thrombotic antiphospholipid syndrome. DOACs should not be the standard treatment for all patients who need to treat or prevent blood clots.
A randomized clinical trial of 1,015 participants found that apixaban did not significantly reduce recurrent stroke risk compared to aspirin in patients with cryptogenic stroke and atrial cardiopathy. The study suggests that alternative treatments may be more effective for preventing stroke recurrence in these patients.
A preliminary study found that most stroke survivors can safely take two common types of antidepressants without increasing the risk of hemorrhagic stroke. However, patients on dual anti-platelet therapy may be at increased risk of bleeding.
Researchers found rivaroxaban associated with nearly 40 bleeding events per 100 patients over a year, while apixaban had similar bleeding events as warfarin but more major bleeds. Apixaban also showed lower mortality rates compared to the other medications.
A Mayo Clinic study found that patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement had lower incidence of mortality and decreased risk of blood clots. The use of warfarin was associated with a 32% reduction in mortality risk, making it an effective treatment for these patients.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A global study found that apixaban reduced the risk of stroke and blood clotting by 37% in patients with device-detected atrial fibrillation, also known as sub-clinical atrial fibrillation (SCAF). The medication also reduced fatal or disabling stroke by 49%.
A phase 4 clinical trial found that apixaban, an anti-clotting medication, reduced the rate of stroke and blood clots in adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms. The study suggests that these individuals may benefit from receiving an anticoagulant.
Researchers found that abelacimab, a Factor XI inhibitor, reduced bleeding compared to rivaroxaban in patients with atrial fibrillation. The study showed significant reduction in hospitalization due to bleeding and almost eliminated gastrointestinal bleeding.
A new study suggests that hormonal contraceptives significantly increase the risk of blood clots, but stopping their use can normalize this risk within two to four weeks. After stopping birth control, clotting markers return to normal levels within one to two weeks and nearly completely by week 12.
A nationwide study found a higher rate of bleeding with standard versus reduced-dose direct oral anticoagulants (DOACs) in older nursing home residents. Reduced-dose DOACs are recommended for many older adults with multiple chronic medical conditions.
A large-scale clinical study confirms the validity of the Vienna Prediction Model in identifying low-risk patients with venous thromboembolism who may not require long-term blood thinning. The model's accuracy was found to be 5.2% after one year for patients with a low relapse risk, but adjustments were made to correct imprecision.
A study found that ultrasound scans performed by emergency physicians can nearly halve the time patients spend in emergency departments. This technology, known as point-of-care ultrasound (POCUS), enables faster diagnoses and treatment for suspected deep vein thrombosis (DVT).
A meta-analysis found that direct oral anticoagulants (DOACs) reduced dementia risk in Asian atrial fibrillation (AFib) patients compared to traditional blood thinners like warfarin. The benefit may reverse with increased age, necessitating further study.
A nationwide study found that modern blood thinners (NOACs) reduce the risk of serious bleeding by up to 45 percent compared to traditional drug Waran. Apixaban, a NOAC substance, is associated with a lower risk of bleeding in both short and long-term treatment.
A new study found that catheter ablation significantly lowers the incidence of cardiovascular events and death in very old patients with nonvalvular atrial fibrillation. The researchers compared 208 patients who underwent AF ablation with those who received medical therapy only, finding a lower risk of both cardiovascular events and de...
Researchers at the University of Tokyo have developed a DNA-based anticoagulant that has shown promising results in test mice and may be ready for human trials soon. The treatment could provide a safer alternative to existing medications, such as heparin, which can cause severe bleeding side effects.
A randomized controlled trial found that time-restricted eating produced similar weight loss results to traditional calorie counting in a racially diverse population of adults with obesity. Participants who engaged in 8-hour time-restricted eating had improved insulin sensitivity compared to those in the control group.
Survivors of firearm injury experience chronic PTSD symptoms and poor health-related quality of life, emphasizing the need for comprehensive care. Screening for chronic kidney disease could be cost-effective for US adults starting at age 35.
A new study by Arianna Anticoagulation Foundation suggests that patients with COVID-19-associated venous thromboembolism may not require prolonged anticoagulant therapy, with a limited duration of 3-6 months being adequate for most patients. The START2-COVID-VTE observational study found low rates of thrombotic recurrences in both groups.
A study by Pusan National University researchers investigates the effects of mild acid hydrolysis on sulfated fucans in sea cucumbers and sea urchins. The results show selective 2-desulfation, leading to an 8-sugar-long oligosaccharide production.
A new study published in the Annals of Internal Medicine shows that direct oral anticoagulant (DOAC) drugs are more effective and cost-effective than low molecular weight heparin for treating cancer-associated thrombosis. The research compared the three DOACs with low molecular weight heparin using a computer model that simulated major...
A cost-effectiveness analysis of direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for cancer-associated thrombosis found that DOACs are more medically effective and cost-effective. The most cost-effective DOAC, apixaban, was also shown to be the least costly anticoagulant.
A trial found that extending anti-clotting treatment after a blood clot in the lower leg reduced further clot risk up to two years. Rivaroxaban administered for three months effectively and safely reduced venous thromboembolism compared to six weeks of treatment.
The November issue of CHEST journal features new guidelines for perioperative management, studies on COVID-19 treatment and COPD treatment, as well as research on sleep apnea and long COVID. These findings have significant implications for patient care and healthcare resource use.
Research conducted at Linköping University found that screening for atrial fibrillation in older people could increase the chance of preventing stroke while saving money for healthcare systems. The study, based on data from the STROKESTOP clinical trial, suggests that screening can be a cost-effective intervention.
A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.
A large-scale comparison of direct oral anticoagulants has identified apixaban as the drug with the lowest risk of bleeding. The study, published in Annals of Internal Medicine, found that apixaban had a 19-28% lower risk of gastrointestinal bleeding compared to other DOACs.
A new daily anti-clotting pill, edoxaban, shows promise in preventing bleeding and clotting instances rare in children with heart conditions. The study's findings indicate edoxaban is a viable alternative to current treatments, eliminating injections and reducing frequent blood tests.
A Swedish cohort study found that direct oral anticoagulants (DOACs) were associated with a lower risk of kidney function decline or kidney failure compared to vitamin K antagonists (VKA). DOACs also showed a lower risk of acute kidney injury.
Researchers analyzed over 6,700 patients treated for blood clots and irregular heart rhythms. Stopping aspirin significantly reduced bleeding complications by 32.3% and prevented one major bleeding event per every 1,000 patients who stopped taking aspirin.
The AABB has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma, recommending its use for nonhospitalized patients at high risk for disease progression. The guidelines suggest that CCP is most effective when transfused with high neutralizing titers early after symptom onset.
The new guideline provides evidence-based recommendations for managing patients on warfarin, DOACs, and antiplatelet drugs before and after surgeries. It aims to minimize preventable bleeding and thrombotic events by standardizing approaches and protocols.